<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Agalsidase beta: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Agalsidase beta: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Agalsidase beta: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="8801" href="/d/html/8801.html" rel="external">see "Agalsidase beta: Drug information"</a> and <a class="drug drug_patient" data-topicid="11163" href="/d/html/11163.html" rel="external">see "Agalsidase beta: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F130769"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Fabrazyme</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52865571"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Fabrazyme</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1056276"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Enzyme, α-galactosidase A</span>;</li>
<li>
<span class="list-set-name">Fabry's Disease, Treatment Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F4806347"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Pretreat with antipyretics (eg, acetaminophen) prior to infusion; patients with prior infusion-related reactions should also receive antihistamines.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2806c8e7-5d91-4e7a-86c0-5f6f8f68f985">Fabry disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fabry disease:</b> Children ≥2 years and Adolescents: IV: 1 mg/kg/dose every 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26546059','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26546059','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity</b>: Patients with IgE antibodies or a positive skin test to agalsidase beta (rechallenge): Children ≥2 years and Adolescents: IV: 0.5 mg/kg/dose every 2 weeks at an initial maximum infusion rate of 0.01 mg/minute; once tolerated, may gradually escalate dose (to maximum of 1 mg/kg/dose every 2 weeks) and/or infusion rate (doubling the infusion rate every 30 minutes to a maximum rate of 0.25 mg/minute) as tolerated.</p></div>
<div class="block dorp drugH1Div" id="F51063383"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, dose adjustment is unlikely to be necessary as agalsidase beta is used to reduce complications of Fabry disease (which includes kidney impairment) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26546059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26546059'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51063384"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F130770"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="8801" href="/d/html/8801.html" rel="external">see "Agalsidase beta: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2806c8e7-5d91-4e7a-86c0-5f6f8f68f985">Fabry disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Fabry disease:</b>
<b>IV:</b> 1 mg/kg every 2 weeks.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991833"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment required.</p></div>
<div class="block doha drugH1Div" id="F50989120"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F130746"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypertension (14%), peripheral edema (21%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (20%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (69% to 83%)</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Infusion site reaction (59%; severe infusion related reaction: 5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Chills (49%), dizziness (21%), fatigue (24%), headache (39%), pain (16%), paresthesia (31%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, back pain (16%), limb pain (19%), myalgia (18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (33%), lower respiratory tract infection (18%), pharyngitis, rhinitis, upper respiratory tract infection (53%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (39%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Chest discomfort (5%), tachycardia (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Excoriation of skin (9%), pruritus (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hot flash (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (≤1%), hypersensitivity reaction (≤1%, including severe hypersensitivity reaction)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Fungal infection (5%), viral infection (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety (6%), burning sensation (6%), depression (6%), falling (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Hypoacusis (5%), tinnitus (8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (9%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (8%), wheezing (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Bradycardia, chest pain, facial edema, flushing, hypotension</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Drowsiness, sensation of cold</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasal congestion, pharyngeal edema</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute myocardial infarction, cardiac failure, cerebrovascular accident, hypersensitivity angiitis, palpitations</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Hyperhidrosis</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Dysphagia, oral hypoesthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphadenopathy</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Hypoesthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Renal failure syndrome</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, hypoxia, respiratory failure</p></div>
<div class="block coi drugH1Div" id="F130758"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed within the US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<i>Canadian labeling</i>: Anaphylaxis to agalsidase beta or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F130744"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Antibody formation: Development of IgG antibodies is common and has been observed within 3 months from the onset of therapy. Some patients may also develop IgE antibodies or skin test reactivity; consider IgE testing in patients with allergic reaction. Rechallenge of patients with IgE-mediated reaction or who have had a positive skin test may be done with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Life-threatening anaphylactic reactions and severe hypersensitivity reactions (eg, angioedema, bronchospasm, chest discomfort, dysphagia, dyspnea, flushing, hypotension, nasal congestion, pruritus, rash, urticaria) have been reported. Patients who develop IgE antibodies may be at a higher risk for hypersensitivity reactions. Stop infusion if severe reactions occur; immediate medical support should be readily available. Consider risks/benefits of readministration following an anaphylactic or severe allergic reaction; some patients have been rechallenged under close clinical supervision; appropriate emergency medications should be immediately available.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Infusion-related reactions are common, and may be severe (chills, vomiting, hypotension, paresthesia); pretreatment with antipyretics and antihistamines is advised. Patients who were positive for anti-Fabrazyme antibodies had an increased incidence of infusion-related reactions. Decrease infusion rate, temporarily discontinue infusion, and/or administer additional antipyretics, antihistamines, and/or steroids to manage infusion reactions. Immediate discontinuation of infusion should be considered for severe reactions. Appropriate medical support for the management of infusion reactions should be readily available. Infusion reactions have occurred despite premedication. Use with caution when readministering to patients with history of infusion reactions.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with compromised cardiac function; may have increased risk of complications from infusion reactions; monitor closely.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Registry: A registry has been created to monitor therapeutic responses and adverse effects during long-term treatment, as well as effects on pregnant and breast-feeding women and their offspring; patients should be encouraged to register (www.registrynxt.com or 1-800-745-4447).</p></div>
<div class="block foc drugH1Div" id="F130753"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fabrazyme: 5 mg (1 ea); 35 mg (1 ea) [contains mouse (murine) and/or hamster protein]</p></div>
<div class="block geq drugH1Div" id="F130740"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16322966"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution (reconstituted)</b> (Fabrazyme Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">5 mg (per each): $1,277.74</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">35 mg (per each): $8,945.68</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52865572"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution Reconstituted, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Fabrazyme: 5 mg (1 ea); 35 mg (1 ea)</p></div>
<div class="block admp drugH1Div" id="F52612187"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">IV: Pretreatment with acetaminophen and an antihistamine is recommended to reduce infusion-related reactions. Administer using 0.2 micron low protein-binding filter. Infusion rate, titration, and maximum infusion rate determined based on weight and presence of antibodies or positive skin test.</p>
<p style="text-indent:-2em;margin-left:2em;">Patient &lt;30 kg: Infusion should be initiated at a rate of 15 mg/hour (0.25 mg/minute); no further titration recommended; maximum infusion rate: 15 mg/hour (0.25 mg/minute).</p>
<p style="text-indent:-2em;margin-left:2em;">Patient ≥30 kg: Infusion should be initiated at a rate of 15 mg/hour (0.25 mg/minute); after tolerance to initial infusion rate is established, the infusion rate may be increased in increments of 3 to 5 mg/hour (0.05 to 0.08 mg/minute) with each subsequent infusions. Administration duration: ≥1.5 hours (based upon individual tolerability).</p>
<p style="text-indent:-2em;margin-left:2em;">Rechallenge: Patients with IgE antibodies or who have had a positive skin test to agalsidase beta: Patients being rechallenged should receive a lower initial infusion rate of 0.6 mg/hour (0.01 mg/minute); after the infusion is tolerated, slowly increase the infusion by doubling the infusion rate every 30 minutes as tolerated to a maximum rate of 15 mg/hour (0.25 mg/minute).</p></div>
<div class="block adm drugH1Div" id="F130755"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Antipyretics should be administered prior to infusion. Infuse through a low protein binding 0.2 micron in-line filter. Initial infusion rate should not exceed 0.25 mg/minute (15 mg/hour). Interrupt or decrease rate in the event of an infusion reaction; may be restarted after resolution of symptoms and/or after administration of antipyretics, antihistamines, and/or steroids. After patient tolerance to the infusion is established, rate may be increased in increments of 0.05-0.08 mg/minute (3-5 mg/hour) with each subsequent infusion. Maximum infusion rate: Patients &lt;30 kg: 0.25 mg/minute; patients ≥30 kg: Infuse over at least 1.5 hours. An initial maximum infusion rate of 0.01 mg/minute should be used for rechallenge in patients with IgE antibodies or who have had a positive skin test to agalsidase beta; may increase infusion rate (doubling the infusion rate every 30 minutes) to a maximum rate of 0.25 mg/minute as tolerated.</p></div>
<div class="block sts drugH1Div" id="F130765"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials between 2°C and 8°C (36°F and 46°F). Product is preservative free; use reconstituted and solutions diluted in NS immediately. If not used immediately, reconstituted and diluted solutions are stable for 24 hours at 2°C and 8°C (36°F and 46°F).</p></div>
<div class="block usep drugH1Div" id="F53565221"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of confirmed Fabry disease (FDA approved in ages ≥2 years and adults).</p></div>
<div class="block mst drugH1Div" id="F2933645"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Agalsidase beta may be confused with agalsidase alfa, alglucerase, alglucosidase alfa</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13298692"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F130747"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May diminish the therapeutic effect of Agalsidase Beta. Management: Avoid concomitant use of amiodarone with agalsidase beta when possible as amiodarone could antagonize intracellular alpha-galactosidase activity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloroquine: May diminish the therapeutic effect of Agalsidase Beta. Management: Avoid concomitant use of chloroquine with agalsidase beta when possible as chloroquine could antagonize intracellular alpha-galactosidase activity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gentamicin (Systemic): May diminish the therapeutic effect of Agalsidase Beta. Management: Avoid concomitant use of gentamicin with agalsidase beta when possible as gentamicin could antagonize intracellular alpha-galactosidase activity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydroxychloroquine: May diminish the therapeutic effect of Agalsidase Beta.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49088717"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Data collection to monitor pregnancy and infant outcomes following exposure to Fabrazyme is ongoing. Females of childbearing potential may enroll in the Fabry registry by calling 1-(800)-745-4447 extension 15500 (www.registrynxt.com).</p></div>
<div class="block pri drugH1Div" id="F130760"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to the use of agalsidase beta in pregnancy is limited (Germain 2010; Madsen 2019; Politei 2010; Senocak Tasci 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to Fabrazyme is ongoing. Pregnant females may enroll in the Fabry registry by calling 1-(800)-745-4447 extension 15500 (www.registrynxt.com).</p></div>
<div class="block mopp drugH1Div" id="F53565220"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Vital signs during infusion; infusion-related reactions; globotriasylceramide (GL3) plasma concentrations; development of IgG or IgE antibodies in patients with suspected allergic reactions (test available from manufacturer).</p></div>
<div class="block pha drugH1Div" id="F130743"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Agalsidase beta is a recombinant form of the enzyme alpha-galactosidase-A, which is required for the hydrolysis of GL-3 and other glycosphingolipids. The compounds may accumulate (over many years) within the tissues of patients with Fabry disease, leading to renal and cardiovascular complications. In clinical trials of limited duration, agalsidase been noted to reduce tissue inclusions of a key sphingolipid (GL-3). It is believed that long-term enzyme replacement may reduce clinical manifestations of renal failure, cardiomyopathy, and stroke. However, the relationship to a reduction in clinical manifestations has not been established.</p></div>
<div class="block phk drugH1Div" id="F130757"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: Mean range: Children: 247 to 1,097 mL/kg; Adults: 81 to 570 mL/kg.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination (dose-dependent): Mean range: Children: 86 to 151 minutes; Adults: 45 to 119 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">Clearance: Children: Mean range: 1.1 to 5.8 mL/minute/kg; Adults: 0.8 to 4.9 mL/minute/kg.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F6038318"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyne</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Fabagal | Fabrazyme | Genzyme fabrazyme</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Fabrazyme</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Fabrazyme.1">
<a name="Fabrazyme.1"></a>Fabrazyme (agalsidase beta) [prescribing information]. Cambridge, MA: Genzyme Corporation; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fabrazyme.2">
<a name="Fabrazyme.2"></a>Fabrazyme (agalsidase beta) [product monograph]. Toronto, Ontario, Canada: Sanofi Genzyme; April 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20045092">
<a name="20045092"></a>Germain DP, Bruneval P, Tran TC, et al. Uneventful pregnancy outcome after enzyme replacement therapy with agalsidase beta in a heterozygous female with Fabry disease: A case report. <i>Eur J Med Genet.</i> 2010;53(2):111-112. doi: 10.1016/j.ejmg.2009.12.004.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/agalsidase-beta-pediatric-drug-information/abstract-text/20045092/pubmed" id="20045092" target="_blank">20045092</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26546059">
<a name="26546059"></a>Hopkin RJ, Jefferies JL, Laney DA, et al. The management and treatment of children with Fabry disease: A United States-based perspective. <i>Mol Genet Metab</i>. 2016;117(2):104-113.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/agalsidase-beta-pediatric-drug-information/abstract-text/26546059/pubmed" id="26546059" target="_blank">26546059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30117110">
<a name="30117110"></a>Madsen CV, Christensen EI, Nielsen R, et al. Enzyme replacement therapy during pregnancy in fabry patients: review of published cases of live births and a new case of a severely affected female with fabry disease and pre-eclampsia complicating pregnancy.<i> JIMD Rep.</i> 2019;44:93-101. doi: 10.1007/8904_2018_129.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/agalsidase-beta-pediatric-drug-information/abstract-text/30117110/pubmed" id="30117110" target="_blank">30117110</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20492401">
<a name="20492401"></a>Politei JM. Treatment with agalsidase beta during pregnancy in Fabry disease. <i>J Obstet Gynaecol Res.</i> 2010;36(2):428-429. doi: 10.1111/j.1447-0756.2009.01164.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/agalsidase-beta-pediatric-drug-information/abstract-text/20492401/pubmed" id="20492401" target="_blank">20492401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26338166">
<a name="26338166"></a>Senocak Tasci E, Bicik Z. Safe and successful treatment with agalsidase beta during pregnancy in fabry disease.<i> Iran J Kidney Dis.</i> 2015;9(5):406-408.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/agalsidase-beta-pediatric-drug-information/abstract-text/26338166/pubmed" id="26338166" target="_blank">26338166</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12896 Version 143.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
